Use of at least one probiotic bacterial strain of Lactobacillus selected from the group consisting of Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313 HEc placumus Lactobac HEAL 19, DSM 15313 99, DSM 15316, Lactobacillus paracasei 8700: 2, DSM 13434, and Lactobacillus paracasei, 02A, DSM13432, for the manufacture of a pharmaceutical composition for the treatment and / or prevention of an autoimmune disease, wherein said autoimmune disease is an autoimmunity Specific organ chosen among multiple sclerosis (MS), psoriasis, rheumatoid arthritis, type I diabetes mellitus or systemic lupus.Uso de al menos una cepa bacteriana probiótica de Lactobacillus seleccionada a partir del grupo compuesto por Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313 y Lactobacillus plantarum HEAL 99, DSM 15316, Lactobacillus paracasei 8700:2, DSM 13434, y Lactobacillus paracasei, 02A, DSM13432, para la fabricación de una composición farmacéutica para el tratamiento y/o prevención de una enfermedad autoinmune, en el que dicha enfermedad autoinmune es una autoinmunidad específica de órgano elegida entre esclerosis múltiple (EM), psoriasis, artritis reumatoide, diabetes mellitus de tipo I o lupus sistémico.
